BSBeate Skinningsrud

Beate Skinningsrud

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Beate Skinningsrud has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • CYP21A2 polymorphisms in patients with autoimmune Addison's disease, and linkage disequilibrium to HLA risk alleles

    by Ingeborg Brønstad, Beate Skinningsrud, Eirik Bratland, Kristian Løvås, Dag Undlien, Eystein Sverre Husebye, Anette Susanne Bøe Wolff

    Objective Steroid 21-hydroxylase, encoded by CYP21A2, is the major autoantigen in autoimmune Addison's disease (AAD). CYP21A2 is located in the region of the HLA complex on chromosome 6p21.3, which harbours several risk alleles for AAD. The objective was to investigate whether CYP21A2 gene variants confer risk of AAD independently of other risk alleles in the HLA loci. Design DNA samples from 381 Norwegian patients with AAD and 340 healthy controls (HC) previously genotyped for the HLA-A, -B, -DRB1, and -DQB1 and MICA loci were used for genotyping of CYP21A2. Methods Genotyping of CYP21A2 was carried out by direct sequencing. Linkage of CYP21A2 to the HLA loci was assessed using UNPHASED version 3.0.10 and PHASE version 2.1. Results Heterozygotes of the single-nucleotide polymorphisms (SNPs) rs397515394, rs6467, rs6474, rs76565726 and rs6473 were detected significantly more frequently in AAD patients compared with HC (PHLA–DRB1 haplotypes. rs6472C protected against AAD (odds ratio=0.15, 95% CI (0.08–0.30), P=3.8×10−10). This SNP was not in an LD with HLA loci (P=0.02), but did not increase protection when considering the effect of HLA–DRB1 alleles. Mutations causing congenital adrenal hyperplasia were found in heterozygosity in Conclusion Genetic variants of CYP21A2 associated to AAD are in LD with the main AAD risk locus HLA-DRB1, and CYP21A2 does not constitute an independent susceptibility locus.


  • Multiple Loci in the HLA Complex Are Associated with Addison's Disease

    by Beate Skinningsrud, Benedicte A. Lie, Ewa Lavant, Joyce A. Carlson, Henry Erlich, Hanne E. Akselsen, Kristina Gervin, Anette B. Wolff, Martina M. Erichsen, Kristian Løvås, et al.

    A strong association between autoimmune Addison's disease (AAD) and major histocompatibility complex class II-encoded HLA-DRB1-DQA1-DQB1 haplotypes is well known. Recent evidence from other autoimmune diseases has suggested that class I-encoded HLA-A and HLA-B gene variants confer HLA-DRB1-DQA1-DQB1-independent effects on disease. We aimed to explore AAD predisposing effects of HLA-A and -B and further investigate the role of MICA and HLA-DRB1-DQA1-DQB1 in a much larger material than has previously been studied. HLA-A, -B, -DRB1, and -DQB1 and a microsatellite in MICA were genotyped in 414 AAD patients and 684 controls of Norwegian origin. The strongest association was observed for the DRB1 locus, in which the DRB1*03:01 and DRB1*04:04 conferred increased risk of AAD, particularly in a heterozygous combination [odds ratio 22.13; 95% confidence interval (11.39-43.98); P = 6 × 10(-20)]. After conditioning on DRB1, association with AAD was still present for HLA-B and MICA, suggesting the presence of additional risk factors. The major histocompatibility complex harbors multiple risk loci for AAD, in which DRB1 appears to represent the main risk factor.


  • The Th17 Pathway Influences Susceptibility to Autoimmune Addison Disease

    by Anna L Mitchell, Katie MacArthur, Anette B Wolff, Beate Skinningsrud, Dag E Undlien, Eystein S Husebye, Simon Hs Pearce

    Autoimmune Addison's disease (AAD) is a rare, highly heritable endocrinopathy with an estimated λsibling (ratio of risk to a sibling vs the unrelated background population) of 160-210. The majority of the genetic risk to AAD has yet to be accounted for. Variants in Th17 pathway genes, including IL-21, 22, 23, 17A and 17F and their receptors may be important in the pathogenesis of autoimmune conditions. We used 7 informative tag-SNPs to investigate 4 candidate genes of the Th17 pathway in subjects with AAD: IL17A (rs4711998, rs3819024, rs16882180), IL17RA (rs2241043, rs6518661), IL21 (rs907715) and IL23A (rs11171806). DNA samples from a cohort of 315 UK and 384 Norwegian AAD patients, and 335 UK and 380 Norwegian controls (total 699 AAD patients, 710 healthy controls) were genotyped using a Sequenom iPlex platform. Ten percent of samples were re-genotyped blind to ensure assay fidelity, all datasets were in Hardy Weinberg equilibrium and McNemar's test confirmed that allele frequencies in the cohorts did not differ significantly. Of the 3 SNPs typed in IL17A, an association with alleles at rs4711998 was seen in the Norwegian AAD cohort (P genotype 0.08, P allele 0.04) and in the cohorts combined (P allele 0.04), however not in the UK cohort. The rs907715 SNP in IL21 was associated with AAD in the UK cohort (P allele 0.01), and in the cohorts combined where the C/C genotype was observed in 319/699 (45.6%) cases compared to 277/710 (39.0%) controls (P genotype 0.01, P allele 0.006), however this association was not replicated in the Norwegian cohort alone (P allele 0.163). The rs11171806 SNP in IL23A was associated with AAD in the UK cohort, where the A/G genotype was found in 31/315 (9.8%) AAD subjects compared to 56/335 (16.7%) controls (P genotype 0.005, P allele 0.007). This SNP was not associated with AAD in the Norwegian cohort (P allele 0.986) and association in the combined cohort failed to reach statistical significance (P allele 0.066). rs22410043 and rs6518661 in IL17RA, and rs3819024, rs16882180 in IL17A were not associated with AAD in any of the cohorts. These data, from the largest collection of AAD patients ever assembled, suggest a contribution to disease susceptibility at the IL17 and IL21 loci, suggesting a role for the Th17 pathway in AAD pathogenesis. We plan to investigate these SNPs in additional AAD patients from other European cohorts to replicate these findings. Sources of Research Support: Medical Research Council; Euradrenal - EU seventh framework programme. Nothing to Disclose: ALM, KM, ABW, BS, DEU, ESH, SHSP

  • Open Access

    A CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-cyclic citrullinated peptide antibody negative rheumatoid arthritis

    by Beate Skinningsrud, Benedicte A Lie, Eystein S Husebye, Tore K Kvien, Øystein Førre, Berit Flatø, Alice Stormyr, Geir Joner, Pål R Njølstad, Thore Egeland, et al.

    Variants in CLEC16A have conferred susceptibility to autoimmune diseases in genome-wide association studies. The present work aimed to investigate the locus' involvements in juvenile idiopathic arthritis (JIA) and further explore the association with rheumatoid arthritis (RA), type 1 diabetes (T1D) and Addison's disease (AD) in the Norwegian population. Three single nucleotide polymorphisms (SNPs) were genotyped in patients with RA (n=809), JIA (n=509), T1D (n=1211) and AD (n=414) and in healthy controls (n=2149). All diseases were associated with CLEC16A, but with different SNPs. The intron 22 SNP, rs6498169, was associated with RA (p=0.006) and JIA (p=0.016) and the intron 19 SNPs, rs12708716/rs12917716, with T1D (p=1x10-5) and AD (p=2x10-4). The RA association was confined to the anti-cyclic citrullinated peptide antibody (anti-CCP) negative subgroup (p=2x10-4). This is the first report of a CLEC16A association with JIA and a split of the RA association according to anti-CCP status. Different causative variants underlie the rheumatic versus the organ specific diseases.


  • Open Access

    X-Linked Congenital Adrenal Hypoplasia with Hypogonadotropic Hypogonadism Caused by an Inversion Disrupting a Conserved Noncoding Element Upstream of theNR0B1(DAX1) Gene

    by Beate Skinningsrud, Eystein S. Husebye, Gregor D. Gilfillan, Eirik Frengen, Aage Erichsen, Kristina Gervin, Eli Ormerod, Thore Egeland, Dag E. Undlien

    Context: X-linked congenital adrenal hypoplasia with hypogonadotropic hypogonadism (AHCH) is known to be caused by coding mutations in the nuclear receptor subfamily 0, group B, member 1 (NR0B1) gene, encoding the transcriptional repressor dosage-sensitive sex-reversal adrenal hypoplasia critical region on the X chromosome protein 1 (DAX1). Objective/Patients: Four males in a family were affected by AHCH. Our aim was to locate the genetic cause of their disease, knowing that they had no mutation in the obvious candidate gene, NR0B1. Design: Linkage analysis of the X chromosome and mutational screening of conserved noncoding regions upstream of NR0B1 were performed. To functionally characterize the genetic defect, studies of transcription and expression of DAX1 and steroidogenic factor 1 (SF-1) were done. Results: A 60 Mb inversion on the X chromosome with one of the inversion breakpoints located in a conserved noncoding region 4 kb upstream of NR0B1 was detected. The inversion causes relocation of a putative SF-1 binding site implicated in murine gonadal development. A reporter construct lacking this enhancer element upstream of NR0B1 was unresponsive to SF-1 transcriptional activation. Immunohistochemistry suggested that the inversion leads to SF-1 silencing in the patients’ testes both in childhood and in adult life. Conclusion: We report a noncoding mutation causing AHCH, an inversion resulting in a phenotype similar to what is caused by intragenic NR0B1 null mutations. The inversion seems to disrupt and/or relocate regulatory sites crucial in DAX1 expression. The 60 Mb X-chromosome inversion causes a phenotype similar to NR0B1 null mutations by disrupting regulatory sites upstream of this gene.


  • Open Access

    Polymorphisms inCLEC16AandCIITAat 16p13 Are Associated with Primary Adrenal Insufficiency

    by Beate Skinningsrud, Eystein S. Husebye, Simon H. Pearce, David O. McDonald, Kristin Brandal, Anette B. Wolff, Kristian Løvås, Thore Egeland, Dag E. Undlien

    Context/Objectives: It is known that different autoimmune diseases often share the same susceptibility genes. In this study we aimed to investigate if loci found associated with common autoimmune diseases in recent genome-wide association studies also could be susceptibility loci for autoimmune Addison’s disease (primary adrenal insufficiency). Design/Patients: A total of 139 tagging single nucleotide polymorphisms (SNPs) in 11 candidate genes (IL2, IL21, IL2RA, CLEC2D, CD69, ERBB3, PTPN11, SH2B3, CLEC16A, CIITA, and PTPN2) were genotyped in a case/control study design consisting of Norwegian Addison’s disease patients (n = 332) and Norwegian healthy control individuals (n = 1029). Five SNPs were subsequently selected for analysis in a United Kingdom sample set consisting of Addison’s disease patients (n = 210) and controls (n = 191). Results: Polymorphisms in CLEC16A and CIITA remained significantly associated with Addison’s disease in the Norwegian sample set at the 0.05 level, even after correction for multiple testing. CLEC16A and CIITA are both located at 16p13, but linkage disequilibrium patterns and logistical regression analyses suggest that SNPs in these two genes are independently associated with Addison’s disease. We were not able to confirm these associations in the United Kingdom material, however, this may well be due to the limited sample size and lack of statistical power. Conclusion: Two alleles at 16p13 are independently associated with the risk of Addison’s disease in the Norwegian population, suggesting this chromosomal region to harbor common autoimmunity gene(s), CLEC16A and CIITA being possible independent candidates.


  • Mutation screening of PTPN22: association of the 1858T-allele with Addison's disease

    by Beate Skinningsrud, Eystein S Husebye, Kristina Gervin, Kristian Løvås, Anne Blomhoff, Anette B Wolff, E Helen Kemp, Thore Egeland, Dag E Undlien

    The tyrosine-protein phosphatase non-receptor type 22 (PTPN22) gene was recently identified as an important genetic susceptibility factor in several autoimmune diseases. The increased risk has been broadly explained by the 1858T-allele (rs2476601). As two smaller studies on Addison's disease (AD) have shown diverging results, we aimed to elucidate the predisposing effect of the single-nucleotide polymorphism (SNP) 1858CT in a larger population of AD patients, especially focusing on the AD patients with known autoimmune etiology. We also screened for unknown rare or common variants in the PTPN22 gene that could predispose for AD. The case–control study of Norwegian AD patients (n=332) and controls (n=990) showed a significant association between autoimmune AD (n=302) and the PTPN22 1858T risk allele (P=0.016). The association of AD with 1858T was supported by a meta-analysis combining our genotype data with that of others published previously (P=0.003). The mutation screening of PTPN22 in AD patients (n=332) and controls (n=112) revealed eight missense variants, five of which have not been reported previously. In conclusion, the 1858T-allele is a PTPN22 genetic susceptibility factor for autoimmune AD. Other rare variants in PTPN22 do occur, and may also be involved in the pathogenesis.